On the contrary, ST VEGFR2 inhibition rapidly increases the tumor vessel lumen and intratumoral flow resulting in improved intratumoral chemotherapy delivery in EAC, while tumor growth is arrested. This evidence concerns the gene KDR and neoplasm.